Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
- PMID: 16636135
- PMCID: PMC3212727
- DOI: 10.1084/jem.20052494
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Figures






Similar articles
-
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.Cancer Res. 2007 Mar 15;67(6):2881-92. doi: 10.1158/0008-5472.CAN-06-3045. Cancer Res. 2007. PMID: 17363612
-
Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.Clin Cancer Res. 2004 Sep 1;10(17):5828-36. doi: 10.1158/1078-0432.CCR-04-0350. Clin Cancer Res. 2004. PMID: 15355913
-
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.J Immunol. 2001 Apr 15;166(8):5300-8. doi: 10.4049/jimmunol.166.8.5300. J Immunol. 2001. PMID: 11290817
-
Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.Scand J Immunol. 2008 Dec;68(6):579-88. doi: 10.1111/j.1365-3083.2008.02175.x. Epub 2008 Oct 22. Scand J Immunol. 2008. PMID: 19000094
-
A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients.Eur J Cancer. 2005 Jun;41(9):1323-30. doi: 10.1016/j.ejca.2005.02.025. Eur J Cancer. 2005. PMID: 15939267
Cited by
-
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Front Oncol. 2021 Apr 21;11:662236. doi: 10.3389/fonc.2021.662236. eCollection 2021. Front Oncol. 2021. PMID: 33968769 Free PMC article. Review.
-
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.Nat Commun. 2024 Aug 23;15(1):7267. doi: 10.1038/s41467-024-51498-0. Nat Commun. 2024. PMID: 39179564 Free PMC article.
-
Targeting Genome Stability in Melanoma-A New Approach to an Old Field.Int J Mol Sci. 2021 Mar 28;22(7):3485. doi: 10.3390/ijms22073485. Int J Mol Sci. 2021. PMID: 33800547 Free PMC article. Review.
-
Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.Front Oncol. 2022 Oct 26;12:1022542. doi: 10.3389/fonc.2022.1022542. eCollection 2022. Front Oncol. 2022. PMID: 36387071 Free PMC article. Review.
-
Origins, genetic landscape, and emerging therapies of small cell lung cancer.Genes Dev. 2015 Jul 15;29(14):1447-62. doi: 10.1101/gad.263145.115. Genes Dev. 2015. PMID: 26220992 Free PMC article. Review.
References
-
- Reits, E.A., J.C. Vos, M. Gromme, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 404:774–778. - PubMed
-
- Schubert, U., L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:770–774. - PubMed
-
- Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J.W. Drijfhout, and J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity. 20:495–506. - PubMed
-
- Reits, E., A. Griekspoor, J. Neijssen, T. Groothuis, K. Jalink, P. van Veelen, H. Janssen, J. Calafat, J.W. Drijfhout, and J. Neefjes. 2003. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 18:97–108. - PubMed
-
- Yewdell, J.W. 2001. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 11:294–297. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous